Parker Waichman LLP

FDA Issues New Warning for Novantrone

Federal regulators have informed healthcare providers of new heart monitoring recommendations or patients being treated with Novantrone.  Novantrone and generic equivalents are approved to treat multiple sclerosis (MS) and cancer. Novantrone has been linked to the development of congestive heart failure. In 2005, the labeling for Novantrone (known generically as mitoxantrone) was changed to recommend […]

Federal regulators have informed healthcare providers of new heart monitoring recommendations or patients being treated with <"https://www.yourlawyer.com/topics/overview/novantrone">Novantrone.  Novantrone and generic equivalents are approved to treat multiple sclerosis (MS) and cancer. Novantrone has been linked to the development of congestive heart failure.

In 2005, the labeling for Novantrone (known generically as mitoxantrone) was changed to recommend that left ventricular ejection fraction (LVEF) be evaluated before initiating treatment and before administering each dose of Novantrone to patients with MS. The 2005 label change was initiated after postmarketing and case reports in the medical literature that described decreases in LVEF or frank congestive heart failure in patients with MS who had received cumulative doses of Novantrone that were lower than 100 mg/m2.  LVEF measures the amount of blood pumped out per beat by the heart’s left ventricle.

Recently, the Food & Drug Administration (FDA) received information from a postmarketing safety study that demonstrated poor adherence to the monitoring recommendations made in 2005 in clinical practice. This study used insurance-claims data and medical-record reviews to examine cardiac monitoring patterns in clinical practice. In this study, it was noted that four patients developed congestive heart failure 4 to 17 months after completing therapy with Novantrone.

The FDA is now working with the manufacturers of Novantrone to remind healthcare professionals of the importance of adhering to the recommendations for patients with MS who are treated with Novantrone and generic equivalents.

The FDA and the manufacturers are now advising that all patients with MS who have finished treatment with mitoxantrone receive yearly quantitative LVEF evaluations to detect late-occurring cardiac toxicity.

The FDA has issued the following recommendations for patients treated with mitoxantrone.

For all patients

  • Assess signs and symptoms of cardiac disease with a history, physical examination, and ECG before initiating therapy with mitoxantrone.
  • Perform a baseline quantitative evaluation of LVEF.

For patients with MS

  • Patients with a baseline LVEF below the lower limit of normal should not be treated with mitoxantrone.
  • Patients should be assessed for cardiac signs and symptoms with a history, physical examination, and ECG before each dose.
  • Patients should undergo a quantitative reevaluation of LVEF before each dose, using the same methodology for each assessment. Additional doses of mitoxantrone should not be administered to patients who have experienced either a drop in LVEF to below the lower limit of normal or a clinically significant reduction in LVEF during mitoxantrone therapy.
  • Patients should not receive a cumulative mitoxantrone dose greater than 140 mg/m2.
  • Patients should undergo yearly quantitative LVEF evaluations after stopping mitoxantrone to monitor for late-occurring cardiotoxicity, using the same methodology that was used for assessments that were done during treatment.

For patients with cancer

  • The possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin should be considered when weighing the benefits and risks of mitoxantrone.
  • The presence or history of cardiovascular disease, previous or concomitant radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or the concomitant use of other cardiotoxic drugs might increase the risk of cardiac toxicity. LVEF should be monitored regularly after the initiation of therapy in patients with these risk factors.
What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
I am so grateful to Julie Trinidad and Maryann who have been amazing every step of the way. They are quick to respond, kept me updated throughout this process and eased my mind by answering all my questions. Thank you again for all your hard work and support.
Allyson Paige
2 months ago
5 Star Reviews 150
Exceptional service ! Extremely knowledgeable. I was treated we respect and dignity everytime I spoke with the staff at Parker Waichman. I want to also thank Gina Viti for always taking my calls and answering all my questions. She was wonderful !
Christian Doran
4 years ago
5 Star Reviews 150
Wow I have never had such a positive review of a law firm and I guess it’s because they never get it all right. This law firm did and they were the ultimate in professional acumen, business acumen and they made what I thought would be a hard process very easy. Tina Morace was the ultimate para legal who when I called and or had a question if was in a call,on vacation or busy made sure to make me a priority and return all my calls within half hr. Service like this makes me and will make me always recommend this law firm and to feel comfortable doing so. Tina’s service I hope will be recognized as she is the ultimate professional and made me feel comfortable for the whole two year process. Have an awesome day and once again they are awesome.
Cleveland Bannister
3 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038